Home / Stocks / MLAB

Mesa Laboratories Inc /Co/ (MLAB, Life Sciences Tools & Services) Stock Valuation & Fair Value Quality business with a solid forward outlook

Mesa Laboratories Inc /Co/ (MLAB, Life Sciences Tools & Services) trades at a blended P/E of 11.8, about 53% below its historical normal valuation, with a forward growth estimate of -2.8%. Analysts' one-year estimates have been hit 27% of the time. Priced at its historical normal P/E of 25.2 on the same blended earnings, the 2026-09-18 close of $126.54 corresponds to about $271 a share. This is a valuation reference, not a price target.

Blended P/E
11.8
Normal P/E
25.2
PEG
Fwd growth
-2.8%
Div yield
0.5%
RSI (14)
69.0
Neutral

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-08-07.

Blended P/E and rating by weekBlended P/E moved from 8.8 to 11.8 between 2026-08-07 and 2026-09-21, against a normal P/E of 25.2, with 0 rating changes over 16 recorded weeks.2026-08-07: P/E 8.8, Quality business with a solid forward outlook (recalculated)2026-08-10: P/E 8.9, Quality business with a solid forward outlook2026-08-14: P/E 8.9, Quality business with a solid forward outlook (recalculated)2026-08-17: P/E 9.8, Quality business with a solid forward outlook2026-08-21: P/E 9.8, Quality business with a solid forward outlook (recalculated)2026-08-24: P/E 11.5, Quality business with a solid forward outlook2026-08-27: P/E 11.5, Quality business with a solid forward outlook (recalculated)2026-08-28: P/E 11.5, Quality business with a solid forward outlook (recalculated)2026-08-30: P/E 11.5, Quality business with a solid forward outlook (recalculated)2026-08-31: P/E 11.9, Quality business with a solid forward outlook2026-09-05: P/E 11.9, Quality business with a solid forward outlook (recalculated)2026-09-07: P/E 11.8, Quality business with a solid forward outlook2026-09-12: P/E 11.8, Quality business with a solid forward outlook (recalculated)2026-09-14: P/E 11.2, Quality business with a solid forward outlook2026-09-19: P/E 11.2, Quality business with a solid forward outlook (recalculated)2026-09-21: P/E 11.8, Quality business with a solid forward outlook10.015.020.025.0Aug 7Aug 18Aug 29Sep 10Sep 21Normal P/E 25.2
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-08-07P/E 8.8-65%Quality business with a solid forward outlook
2026-08-31P/E 11.9-53%Quality business with a solid forward outlook
2026-09-21P/E 11.8-53%Quality business with a solid forward outlook ← now

Frequently asked questions

Is Mesa Laboratories Inc /Co/ stock overvalued?

At a blended P/E of 11.8 versus its historical normal P/E of 25.2, Mesa Laboratories Inc /Co/ trades about 53% below its typical valuation. tickerseer currently rates it quality business with a solid forward outlook.

What is Mesa Laboratories Inc /Co/'s fair value and PEG?

Mesa Laboratories Inc /Co/ trades at a blended P/E of 11.8 against a historical normal P/E of 25.2, a forward growth estimate of -2.8%. Priced at its historical normal P/E of 25.2 on the same blended earnings, the 2026-09-18 close of $126.54 corresponds to about $271 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Mesa Laboratories Inc /Co/ changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-08-07.

Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.